R&D Trends

Incyte, Agenus ink global alliance to develop novel immuno-oncology antibodies

Monday, January 12, 2015 02:42 PM

Incyte, a Wilmington, Del.-based biopharmaceutical company, and Agenus, an immuno-oncology company based in Lexington, Mass., have formed a global license, development and commercialization agreement focused on novel immuno-therapeutics using Agenus' proprietary Retrocyte Display antibody discovery platform.

More... »


X-Chem collaborates with Janssen and Johnson & Johnson Innovation

Monday, January 12, 2015 02:40 PM

X-Chem, a privately held biotechnology company based in Waltham, Mass., applying its drug discovery platform to the generation of novel small molecule therapeutics, has announced a multi-target collaboration with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.  The collaboration, which is being facilitated by Johnson & Johnson Innovation, Boston, focuses on the discovery and development of candidate molecules for the treatment of inflammatory diseases.

More... »


Report: Sponsors will boost productivity, control R&D costs in 2015

Friday, January 9, 2015 01:54 PM

Drug developers will implement strategies over the next year to improve clinical study performance to help control R&D costs and boost overall productivity, while increasing their focus on the development of cost-effective therapies that can help lower healthcare spending, according to the Tufts Center for the Study of Drug Development (CSDD).

More... »

Tetragenetics, MedImmune collaborate on ion channel drug discovery program

Thursday, January 8, 2015 01:03 PM

Tetragenetics, an emerging biotechnology company based in Cambridge, Mass., will collaborate with MedImmune, the global biologics R&D arm of AstraZeneca, on antibody drug discovery research. Specifically, Tetragenetics will use its proprietary ion channel production technology, SionX, to produce up to five ion channel antigens for MedImmune's antibody drug discovery programs.

More... »

23andMe, Genentech partner to analyze genomic data for Parkinson’s

Thursday, January 8, 2015 01:00 PM

23andMe, a privately held personal genomics and biotechnology company based in Mountain View, Calif., has inked an agreement with Genentech, a member of the Roche Group, to generate whole genome sequencing data for approximately 3,000 people in 23andMe’s Parkinson’s disease community. The goal of the collaboration is to identify new therapeutic targets for treating Parkinson’s disease.

More... »

Isis Pharmaceuticals, Janssen collaborate

Wednesday, January 7, 2015 12:59 PM

Isis Pharmaceuticals, based in Carlsbad, Calif., has entered into a global collaboration with Janssen Biotech to discover and develop antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract. The collaboration brings together Isis' RNA-targeted technology platform and the expertise of Janssen in autoimmune disorders and therapeutic formulation to discover and develop antisense drugs that can be locally administered, including oral delivery, to treat autoimmune disorders in the GI tract.

More... »

Intellia Therapeutics, Novartis partner

Wednesday, January 7, 2015 12:40 PM

Intellia Therapeutics, a Cambridge, Mass.-based developer of therapeutic products using CRISPR/Cas9 technology for gene editing and repair, has announced a five-year R&D collaboration with Novartis to accelerate the ex vivo development of new CRISPR/Cas9-based therapies using chimeric antigen receptor T cells (CARTs) and hematopoetic stem cells (HSCs).

More... »

Sevion, Johnson & Johnson Innovation, Janssen collaborate for antibody discovery

Monday, January 5, 2015 12:40 PM

Sevion Therapeutics, which discovers, develops and acquires next-generation biologics, is collaborating with CNA Development, an affiliate of Janssen Pharmaceuticals, to discover antibodies using Sevion's spatially addressed library platform.

More... »

Lilly inks diabetes research partnership with University of Surrey

Monday, January 5, 2015 12:39 PM

Eli Lilly has announced a five-year research partnership with U.K.-based University of Surrey to study health outcomes, focusing on the effects of treatment in people with type 2 diabetes, which affect about 95% of those with the disease.

More... »

Amgen, Kite Pharma form cancer immunotherapy collaboration

Monday, January 5, 2015 12:37 PM

Amgen and Santa Monica, Calif.-based Kite Pharma have entered into a strategic research collaboration and license agreement to develop and commercialize the next generation of novel Chimeric Antigen Receptor (CAR) T cell immunotherapies based on Kite's engineered autologous cell therapy (eACT) platform and Amgen's extensive array of cancer targets.

More... »

CenterWatch
CWWeekly

January 19

Roche takes $1B majority stake in Foundation Medicine to use genomic testing to personalize oncology treatments

BRANY launches software, iPad app to streamline protocol creation for investigator-initiated trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs